CA
NZ
UK
AU
IND
US
● CDT shares slid 17.67% with no fresh, verifiable news catalyst, extending a decline that has erased roughly 99% ofShareholdervalue over the trailing twelve months.
ArriVent BioPharma (NASDAQ:AVBP) rose 10.93% to about $31.35, extending a strong year for the clinical-stage oncology company and lifting its market capitalization to roughly $1.55 billion. The move reflects growing investor conviction in ArriVent's lead lung-cancer program and an expanding pipeline that has drawn …
Agenus (NASDAQ:AGEN) rose 9% as immuno-oncology names attracted renewed interest and as the company advanced its lead cancer-drug program toward a registrational milestone. The Massachusetts biotech has spent 2026 trying to convert a promising but capital-hungry pipeline into a clearer commercial path, and recent …
Absci (NASDAQ:ABSI) gained 8.94% as investors returned to artificial-intelligence-driven drug-discovery names, a theme that has moved in and out of favor through 2026. The company uses generative AI and wet-lab experimentation to design antibodies, and its stock tends to track sentiment toward the broader …
● HCWB shares rose 12.55% after the company's second-quarter update on HCW9302, showing all three patients in a second dose cohort achieved at least a 25% reduction in SALT scores for alopecia areata.
● Picard Medical shares surged roughly 86% after second-quarter 2026Revenueof about $2.95 million nearly doubled the consensus estimate near $1.55 million.
● APLM shares climbed 14.68% in a sharp countertrend bounce after a prolonged decline driven by the company's small scale and dilution risk.
● CUE shares gained roughly 15%, extending a striking year as the company broadens its pipeline beyond its original oncology roots.
● IFRX shares rocketed 20% without a clearly identifiable, same-day company-specific catalyst, characteristic of a small-cap biotech with a modest float.
● PRME shares climbed 14.15% amid a broadly firmer tape for advanced-therapy names, without a single Prime-specific disclosure behind the move.
Please wait processing your request...